TIL

Instil Bio Inc

Add to Watchlist

Advanced Chart

28.440

+0.82(2.969%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

28.940

Open

27.780

VWAP

27.60

Vol

152.83K

Mkt Cap

186.63M

Low

26.700

Amount

4.22M

EV/EBITDA(TTM)

Total Shares

6.50M

151.79M

EV/OCF(TTM)

P/S(TTM)

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. The Company’s subsidiary, Axion Bio, Inc., in-licensed certain bispecific antibodies, including AXN-2510/IMM2510 and AXN-27M/IMM27M, a monoclonal antibody targeting cytotoxic T-lymphocyte associated antigen 4, or CTLA-4. AXN-2510/IMM2510, the lead in-licensed product candidate, is a novel and differentiated PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumor cancers. AXN-27M/IMM27M is an antibody-dependent cellular cytotoxicity-enhanced monoclonal antibody targeting CTLA-4, which has been designed to promote intratumoral regulatory T cell depletion to enhance the efficacy and reduce the toxicity associated with first-generation anti-CTLA-4 antibodies.

2 Analyst Rating

339.52% Upside

Wall Street analysts forecast TIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TIL is 125.00 USD with a low forecast of 125.00 USD and a high forecast of 125.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

339.52% Upside

Current: 28.440

Low

125.00

Averages

125.00

High

125.00

339.52% Upside

Current: 28.440

Low

125.00

Averages

125.00

High

125.00

H.C. Wainwright

Buy

maintain

$105 -> $125

2025-05-23

Reason

H.C. Wainwright

Price Target

$105 -> $125

2025-05-23

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Instil Bio to $125 from $105 and keeps a Buy rating on the shares after the company released Phase 1/2 dose escalation data for AXN-2510 in first-line non-small cell lung cancer. The firm increased its probability of approval to 35% from 25%.

H.C. Wainwright

Buy

downgrade

$110 -> $105

2025-05-22

Reason

H.C. Wainwright

Price Target

$110 -> $105

2025-05-22

downgrade

Buy

Reason

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$110

2025-03-05

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$110

2025-03-05

Reiterates

Strong Buy

Reason

JMP Securities

Chris Muller

Hold

Reiterates

n/a

2025-02-13

Reason

JMP Securities

Chris Muller

Price Target

n/a

2025-02-13

Reiterates

Hold

Reason

Jefferies

Kelly Shi

Hold

Strong Buy

Upgrades

$11 → $52

2025-01-07

Reason

Jefferies

Kelly Shi

Price Target

$11 → $52

2025-01-07

Upgrades

Hold

Strong Buy

Reason

Jefferies upgraded Instil Bio to Buy from Hold with a price target of $52, up from $11.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Reiterates

$110

2024-11-18

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$110

2024-11-18

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Instil Bio Inc (TIL.O) is -2.35, compared to its 5-year average forward P/E of -4.40. For a more detailed relative valuation and DCF analysis to assess Instil Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.40

Current PE

-2.35

Overvalued PE

0.41

Undervalued PE

-9.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.27

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

2.34

Undervalued EV/EBITDA

-8.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3027.08

Current PS

0.00

Overvalued PS

13193.04

Undervalued PS

-7138.87

Financials

Annual

Quarterly

FY2025Q1

N/A

Total Revenue

FY2025Q1

YoY :

-26.42%

-14.48M

Operating Profit

FY2025Q1

YoY :

+16.04%

-28.20M

Net Income after Tax

FY2025Q1

YoY :

+15.51%

-4.32

EPS - Diluted

FY2025Q1

YoY :

-70.85%

-4.20M

Free Cash Flow

FY2025Q1

N/A

Gross Profit Margin - %

FY2025Q1

N/A

FCF Margin - %

FY2025Q1

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

38.9K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

355.5K

Volume

Months

0-12

355.5K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

TIL News & Events

Events Timeline

2025-07-02 (ET)

2025-07-02

06:01:35

Instil Bio announces FDA clearance of IND application for AXN-2510

2025-06-11 (ET)

2025-06-11

07:16:04

Instil Bio adds Maraganore to the Board of Directors of Axion Bio

2025-06-02 (ET)

2025-06-02

07:25:37

Instil Bio appoints Jamie Freedman as CMO

News

9.0

07-02Newsfilter

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

9.0

07-02NASDAQ.COM

Instil Bio Announces Clearance Of AXN-2510 IND

2.0

06-20NASDAQ.COM

Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know